cbdMD (NYSEAMERICAN:YCBD) Earns Hold Rating from Maxim Group

cbdMD (NYSEAMERICAN:YCBD – Get Free Report)‘s stock had its “hold” rating reissued by analysts at Maxim Group in a report issued on Monday,Benzinga reports.

cbdMD Stock Performance

Shares of YCBD stock opened at $0.50 on Monday. cbdMD has a 12 month low of $0.47 and a 12 month high of $2.56. The stock has a 50-day moving average price of $0.64 and a 200 day moving average price of $0.74.

Get cbdMD alerts:

cbdMD (NYSEAMERICAN:YCBD – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.08). cbdMD had a negative net margin of 13.80% and a negative return on equity of 34.26%. The business had revenue of $5.55 million during the quarter, compared to the consensus estimate of $5.69 million.

Hedge Funds Weigh In On cbdMD

An institutional investor recently bought a new position in cbdMD stock. Jane Street Group LLC bought a new position in shares of cbdMD, Inc. (NYSEAMERICAN:YCBD – Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 51,141 shares of the company’s stock, valued at approximately $69,000. Jane Street Group LLC owned approximately 0.49% of cbdMD at the end of the most recent quarter. 7.18% of the stock is currently owned by hedge funds and other institutional investors.

About cbdMD

(Get Free Report)

cbdMD, Inc (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.

The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities.

Featured Articles

• Five stocks we like better than cbdMD
• 3 ETFs Built to Protect Your Money if the Bull Market Breaks
• JFrog’s AI Opportunity Could Fuel a Big Leap in Share Price
• Is SiTime the Best AI Stock You’ve Never Heard Of?
• The Metals Company’s Big Bet Now Comes Down to a License

Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.